Objective | The dose regimen should achieve a trough level of IgG (measured before the next infusion) of at least 5 to 6 g/l and aim to be within the reference interval of serum IgG for age |
Loading dose (if required) | 0.2 to 0.5g/kg. This may need to be divided over several days, with a maximal daily dose of 0.1 to 0.15 g/kg |
Maintenance dose | After steady state IgG levels have been attained, maintenance doses are administered to reach a cumulative monthly dose of the order of 0.4-0.8 g/kg |
Trough levels | Trough levels should be measured and assessed in conjunction with the incidence of infection |
Dose adjustment | To reduce the rate of infection, it may be necessary to increase the dose and aim for higher trough levels |
Dosing and Administration
Dosing and administration1
Primary immunodeficiency syndromes1
Secondary immunodeficiencies1
Recommended dose | The recommended dose administered at repeated intervals (approximately once per week) is to reach a cumulative monthly dose of the order of 0.2-0.4 g/kg. |
Trough levels | IgG trough levels should be measured and assessed in conjunction with the incidence of infection |
Dose adjustment | Dose should be adjusted as necessary to achieve optimal protection against infections, an increase may be necessary in patients with persisting infection; a dose decrease can be considered when the patient remains infection free |
Cutaquig® dosage calculator
Administration1
Administration route | Cutaquig® should be administered via the subcutaneous route |
Infusion frequency | Cutaquig® can be administered at regular intervals from daily up to every other week |
Infusion sites | Abdomen, thigh, upper arm, and lateral hip. Infusion sites should be at least 5 cm apart. There is no limit to the number of infusion sites. Each single dose may need to be injected at different anatomic sites |
Infusion rate* | Initially 15 mL/h/site. From infusion 7 on, if well tolerated, the infusion rate can be gradually increased to 25 ml/h/site. Recommended infusion rate per hour for all sites combined: 30 ml/h for first 6 infusions, then gradually increase to 50 ml/h and, if well tolerated to 80 ml/h |
Infusion volume per site | Infants and children: infusion site may be checked every 5-15 mL. Adults: doses over 30 mL may be divided according to patient preference |
*Please consult your local cutaquig® Summary of Product Characteristics for more detailed instructions.
The low viscosity of cutaquig® makes it easy to use and administer2
Administration Video
References:
1. Cutaquig® Summary of Product Characteristics. January 2022.
2. Gelbmann, N., et al., Octanorm [cutaquig®], a new immunoglobulin (human) subcutaneous 16.5% solution for injection (165 mg/mL) – biochemical characterization, pathogen safety, and stability. Biologicals, 2019. 60:60-67.
This is an international website for cutaquig® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
▼ This medicinal product is subject to additional monitoring.